

A 1
Concl'd

least 200 mg/day, said amount being sufficient to decrease albumin excretion rate without causing adverse side effects.

27 (once amended). The method of claim 26 wherein Sulodexide or salt thereof is administered orally as a tablet, a capsule or a liquid suspension.

A 2

29 (once amended). The method of claim 26 wherein the Sulodexide or salt thereof is administered in a single or divided dose from one to four times per day.

30 (new). The method of claim 26 wherein Sulodexide or salt thereof is administered orally as a tablet, coated tablet, caplet, hard gelatin capsule, soft gelatin capsule, troche, dragee, dispersion, suspension or solution.

31 (new). The method of claim 26 wherein the amount of Sulodexide or salt thereof administered is at least 225 mg/day.

A 3

32 (new). The method of claim 26 wherein the amount of Sulodexide or salt thereof administered is at least 250 mg/day.

33 (new). The method of claim 26 wherein the amount of Sulodexide or salt thereof administered is at least 275 mg/day.

34 (new). The method of claim 26 wherein the amount of Sulodexide or salt thereof administered is at least 300 mg/day.

35 (new). The method of claim 26 wherein the amount of Sulodexide or salt thereof administered is at least 400 mg/day.

36 (new). The method of claim 26 wherein the amount of Sulodexide or salt thereof administered is at least 525 mg/day.

REMARKS

Claims 26, 27 and 29-36 will be pending and under consideration in the present application upon entry of the present amendments.

Claims 1-25 and 28 have been canceled without prejudice in order to expedite issuance of claims to certain embodiments of the invention in the present application. Applicants reserve the right to prosecute the subject matter of these claims in a related continuation or divisional application.

Claims 26, 27 and 29 have been amended in order to more clearly claim certain embodiments of the invention. The amendments are made in order to recite more